Vertex Pharmaceuticals, Inc. (VRTX) Tops Q4 EPS by 16c

Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q4 EPS of $0.86, $0.16 better than the analyst estimate of $0.70. Revenue for the quarter came in at $563.3 million versus the consensus estimate of $518.36 million.

For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• YesAsia Holdings Replicates Record High Half-Year Results: Revenue Grows 23.2% to US$301.51 Million; Net Profit Surges 30.0% to US$18.30 Million
• Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak